Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2012

01-08-2012 | Letter to the Editor

MRI in residual tumor size measurement in patient with breast cancer receiving neoadjuvant chemotherapy calls for caution

Authors: Lian-Ming Wu, Jiani Hu, Jian-Rong Xu

Published in: Breast Cancer Research and Treatment | Issue 1/2012

Login to get access

Excerpt

We would like to thank Dr. Marc Lobbes for his thoughtful reading of our recent article on magnetic resonance imaging (MRI) in breast cancer patients receiving neoadjuvant chemotherapy (NAC) which published on Breast Cancer Research and Treatment [1].We also appreciate the comments from Dr. Marc Lobbes. The letter by him addresses an important issue regarding the value of MRI in the evaluation of residual disease in the patient with breast cancer receiving NAC. He stated rates of pathologic complete response (pCR) may vary, the majority of patients receiving NAC do not reach pCR, and the value of MRI in these patients was not discussed in our study. When we initially designed the study, we intended to analysis the partial regression in breast cancer patient receiving NAC. However, this is a very controversial subject, and we are not surprised that other investigators have critiques of our survey. …
Literature
1.
Wu LM, Hu JN, Gu HY, Hua J, Chen J, Xu JR (2012) Can diffusion-weighted MR imaging and contrast-enhanced MR imaging precisely evaluate and predict pathological response to neoadjuvant chemotherapy in patients with breast cancer? Breast Cancer Res Treat. doi:10.​1007/​s10549-012-2033-5
2.
Wasser K, Sinn HP, Fink C et al (2003) Accuracy of tumor size measurement in breast cancer using MRI is influenced by histological regression induced by neoadjuvant chemotherapy. Eur Radiol 13:1213–1223PubMed
3.
Nakahara H, Yasuda Y, Machida E et al (2011) MR and US imaging for breast cancer patients who underwent conservation surgery after neoadjuvant chemotherapy: comparison of triple negative breast cancer and other intrinsic subtypes. Breast Cancer 18(3):152–160PubMedCrossRef
4.
Warren RM, Bobrow LG, Earl HM et al (2004) Can breast MRI help in the management of women with breast cancer treated by neoadjuvant chemotherapy? Br J Cancer 90(7):1349–1360PubMedCrossRef
5.
Rieber A, Brambs HJ, Gabelmann A, Heilmann V, Kreienberg R, Kühn T (2002) Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy. Eur Radiol 12(7):1711–1719PubMedCrossRef
6.
Rieber A, Zeitler H, Rosenthal H, Görich J, Kreienberg R, Brambs HJ, Tomczak R (1997) MRI of breast cancer: influence of chemotherapy on sensitivity. Br J Radiol 70(833):452–458PubMed
7.
Dinnes J, Deeks J, Kirby J, Roderick P (2005) A methodological review of how heterogeneity has been examined in systematic reviews of diagnostic test accuracy. Health Technol Assess 9(12):1–113
Metadata
Title
MRI in residual tumor size measurement in patient with breast cancer receiving neoadjuvant chemotherapy calls for caution
Authors
Lian-Ming Wu
Jiani Hu
Jian-Rong Xu
Publication date
01-08-2012
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2012
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-012-2182-6

Other articles of this Issue 1/2012

Breast Cancer Research and Treatment 1/2012 Go to the issue

Preclinical Study

Oncogene amplification in male breast cancer: analysis by multiplex ligation-dependent probe amplification

Epidemiology

Impact of comorbidity on management and mortality in women diagnosed with breast cancer

Preclinical Study

Auto-acetylation stabilizes p300 in cardiac myocytes during acute oxidative stress, promoting STAT3 accumulation and cell survival

Preclinical study

Whole genome in vivo RNAi screening identifies the leukemia inhibitory factor receptor as a novel breast tumor suppressor

Preclinical Study

High and low mammographic density human breast tissues maintain histological differential in murine tissue engineering chambers

Epidemiology

Stage-specific breast cancer incidence rates among participants and non-participants of a population-based mammographic screening program
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits